Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02742935
Recruitment Status : Active, not recruiting
First Posted : April 19, 2016
Last Update Posted : October 25, 2019
Sponsor:
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Tracking Information
First Submitted Date  ICMJE April 14, 2016
First Posted Date  ICMJE April 19, 2016
Last Update Posted Date October 25, 2019
Actual Study Start Date  ICMJE April 27, 2016
Actual Primary Completion Date May 6, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 19, 2016)
dose limited toxicity [ Time Frame: 28day ]
according to NCI CTCAE V4.03 to evaluate the toxicity
Original Primary Outcome Measures  ICMJE
 (submitted: April 18, 2016)
dose limited toxicity [ Time Frame: 28day ]
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Official Title  ICMJE An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumor
Brief Summary This is an open-label, single center, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors. The primary objective is to assess safety and tolerability of SHR-1210 and identify recommended phase II doses of SHR-1210 in patients with advanced solid tumors.
Detailed Description

This is an open-label, single center, nonrandomized, dose-escalation Phase 1 study to evaluate safety and tolerability of SHR-1210 in subjects with advanced Solid Tumors who have failed current standard antitumor therapies.

The safety and tolerability of SHR-1210 will be assessed by ongoing reviews of clinical laboratory tests, Eastern Cooperative Oncology Group (ECOG) performance status, physical examination, electrocardiogram (ECG), and adverse events. Evaluations of immune safety will also be conducted (immune-related AEs, or labs of autoimmune sera, inflammatory events, and immunogenicity). Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

Efficacy will be assessed every 8 weeks. The study consists of 3 periods: screening (up to 14 days before the first dose), treatment, and follow-up (up to 3 months after the last dose of study treatment).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Breastcancer
  • Gastrointestinal Cancer
Intervention  ICMJE Biological: SHR-1210
A fully human monoclonal immunoglobulin (IgG4 subtype)
Study Arms  ICMJE Experimental: Injection SHR-1210
SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes.
Intervention: Biological: SHR-1210
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: January 17, 2019)
99
Original Estimated Enrollment  ICMJE
 (submitted: April 18, 2016)
36
Estimated Study Completion Date  ICMJE October 2019
Actual Primary Completion Date May 6, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female 18-65 years of age;
  2. Histologically confirmed solid tumor ;
  3. Documented as advanced disease(unresectable or metastatic disease), failure to standard therapies or lack of standard therapy;
  4. ECOG performance status of 0 or 1;
  5. Life expectancy ≥ 12 weeks.;
  6. Ideally, subjects enrolled have measurable lesion(s) according to RECIST v1.1/mRECIST(liver cancer);
  7. Adequate laboratory parameters during the screening period as evidenced by the following:

    1. Absolute neutrophil count ≥ 1.5 × 109/L ;
    2. Platelets ≥ 100 × 109/L;
    3. Hemoglobin ≥ 9.0 g/dL;
    4. Albumin (ALB) levels ≥ 2.8 g/dL
    5. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), ALT and AST ≤ 1.5

      • ULN; for subjects with liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN;
    6. Creatinine clearance≥50 mL/min;
  8. Female and male who have reproductive potential must be willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy while on treatment and for at least 3 months after receiving the last dose of study treatment. Women of childbearing potential with pregnancy test negative within 7days before entering the group and not in in lactation;
  9. Able to understand and sign an informed consent form (ICF).

Exclusion Criteria:

  1. Subjects with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy, asthma that requires intermittent use of bronchodilators can not be included;
  2. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before entering the group;

3 History of organ transplantation (except corneal transplantation);

4. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR-1210 formulation;

5 History or concurrent with other malignant disease, except completely cured basal cell skin cancers and carcinoma in situs of cervix;

6. Presence of symptomatic central nervous system (CNS) metastases (indicated cerebral edema, steroid requirement, or progressive disease), Subjects with brain or meningeal metastases that were previously treated must be clinically stable (MRI) for at least 2 months, and have discontinued systemic steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug administration;

7. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) >2 NYHA 2 congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

8. Prior radiotherapy, systemic chemotherapy (< 6 weeks if chemotherapy including nitrosoureas or mitomycin), hormone therapy, surgery or target therapy within 4 weeks before the study drug administration, or any unresolved AEs > CTC-AE Grade 1;

9. Active infection or an unexplained fever > 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);

10. History of immunodeficiency (HIV) or active hepatitis;

11. Participation in a clinical study or less than 1 month from the last dose of investigational drug to sign ICF;

12. May require for other systemic anti-tumor therapy during the study period;

13. History of PD-1/PD-L1 therapy;

14. History of psychotropic substance abuse, alcoholism or drug abuse;

15. Other factors that may lead to the termination of the participation in the study at the discretion of the investigators.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02742935
Other Study ID Numbers  ICMJE SHR-1210-103
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Jiangsu HengRui Medicine Co., Ltd.
Study Sponsor  ICMJE Jiangsu HengRui Medicine Co., Ltd.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Qing Yang, Doctor Jiangsu Hengrui Pharmaceutical Co., Ltd.
PRS Account Jiangsu HengRui Medicine Co., Ltd.
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP